Johnson & Johnson (NYSE: JNJ) expanded the rollout of its latest Tecnis Odyssey presbyopia-correcting intraocular lenses ...

Shares in Bausch + Lomb were higher after the company received approval from the Food and Drug Administration for its enVista Envy full range of vision intraocular lens. Shares were recently up 23% at ...

Cooper’s pricing power and cost optimization efforts are expected to drive margin expansion. Read why I reiterate a Buy ...

Actual IOL placement relative to the reference ... Finally, lens rotation was estimated using the data from Alcon provided in the lens labeling. The average rotation reported in the Directions ...

Bausch + Lomb Corp. (BLCO, BLCO.TO) announced that the U.S. Food and Drug Administration has approved the enVista Envy full range of ...

Alcon Inc.’s ALC growth is driven by its ... banking on advanced technology intraocular lenses, including Vivity, PanOptix and monofocaltorics in international markets. In Consumables, sales ...

Alcon's core business revolves around eye care products, with a significant presence in the implantables market. The company's portfolio includes intraocular lenses (IOLs), surgical equipment ...

Dublin, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The "Global Intraocular Lens Injector Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Product Type, End-User, Technology ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 03, 2024 (GLOBE NEWSWIRE) -- The "Intraocular Lens (IOL) - A Global market Overview" report has been added to ResearchAndMarkets.com's offering.

Bausch + Lomb said enVista Envy intraocular lenses will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. The company is in the process of seeking ...

Alcon's core business revolves around eye care products, with a significant presence in the implantables market. The company's portfolio includes intraocular lenses (IOLs), surgical equipment, and ...